Apidra Approval History

• FDA approved: Yes (First approved April 16th, 2004)
• Brand name: Apidra
• Generic name: insulin glulisine
• Company: Aventis Pharmaceuticals Inc.
• Treatment for: Diabetes, Type 1, Diabetes, Type 2

Apidra (insulin glulisine) is a rapid-acting recombinant DNA human insulin analogue used for the control of hyperglycemia in patients with diabetes mellitus.

FDA Approval History for Apidra

Date	Article
Feb 26, 2009	FDA Approves Apidra SoloSTAR - a Prefilled Disposable Insulin Pen
Oct 29, 2008	FDA Approves Rapid-Acting Insulin Apidra for Treatment of Children with Diabetes
Jun 15, 2007	FDA Approves New Route of Administration for Rapid-Acting Apidra Providing an Additional Treatment Option for Hospitalized Diabetes Patients with High Blood Sugar Levels
Apr 16, 2004	Apidra Aventis Pharmaceuticals Inc. - Treatment for Diabetes Mellitus

See also...

Apidra (insulin glulisine) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.